Hemogenyx gets approval for Phase 1 trial of promising leukemia therapy
() , a biopharma company developing therapies for blood diseases, said it has received IRB approval for a Phase 1 clinical trial of its lead asset HEMO-CAR-T for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML) in adults. Following approval by the International Review Board, HEMO-CAR-T was given the formal designation HG-CT-1.
Hemogenyx's Phase 1 trial for HG-CT-1 will be a dose escalation study, with its primary objective to assess the safety of the treatment in adult patients with R/R AML. Secondary objectives include estimating the efficacy of the treatment, the overall survival, progression-free survival, and duration of response in evaluable subjects.
Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, commenting: "We are excited to receive IRB approval to proceed with our Phase I clinical trial of HEMO-CAR-T. This trial is a critical step in the development of our CAR-T therapy for AML patients who have exhausted other treatment options. With this study, we aim to establish the safety profile of HG-CT-1 and gather preliminary efficacy data that could pave the way for future therapeutic development."
View from Vox
Hemogenyx (mktcap £22.6m) clears a regulatory hurdle in the development of its flagship treatment for R/R AML, now known as HG-CT-1. The asset has been cleared by the IRB for a Phase 1 study that will evaluate its safety as well as number of key secondary characteristics. The secondary objectives are crucial for assessing the broader impact of HG-CT-1 and include efficacy, survival, and duration of response metrics.
The study will pave the way for commercialisation of HG-CT-1, a promising treatment for patients with R/R AML who currently have few therapeutic options. AML is the most common type of acute leukemia in adults. It has poor survival rates, with a 5-year rate of less than 30% in adults. It is currently treated with chemotherapy rather than potentially more benign and effective forms of therapy such as 's HG-CT-1.
The successful development of a new therapy for AML would have a major impact on treatment and survival rates for the disease, and would be a major value inflection point for . Overall, IRB approval marks a significant milestone for the now clinical-stage company, enabling it to advance its disruptive lead therapy into clinical testing at one of the world's top cancer research institutions. Markets welcomed the news, driving shares 14% higher in early Friday trade.
recently raised £600k from an institutional investor for the Phase 1 clinical trial of HG-CT-1, adding to £3.32m raised in 1H24 for the asset and leaving sufficient runway to continue development. In 1H24, narrowed its pre-tax loss to £2.82m from £4.32m in 1H23.
Follow News & Updates from Hemogenyx Pharmaceuticals:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.